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Introduction
The identification of biomarkers with prognostic and predictive 
value enables oncologists to select a more efficient and less toxic 
therapy for their patients on the basis of individual tumor charac-
teristics. Data from recent clinical trials point towards 2 agents for 
the targeted treatment of BRCA mutation carriers with breast or 
ovarian cancer: platinum-containing chemotherapies and poly-
ADP-ribose polymerase inhibitors (PARPi). In vitro both sub-
stances lead to apoptotic cell death of BRCA-deficient tumor cells 
albeit using different mechanisms. The shared drug target is the 
absence of homologous recombination in BRCA-deficient tumor 
cells. Homologous recombination is an error-free repair mecha-
nism of DNA double-strand breaks (DSB) [1]. The absence of ho-
mologous recombination activates error-prone DSB mechanisms 
like non-homologous end joining resulting in genomic instability 
of the cells. Platinum compounds cause DNA crosslinks that lead 
to DSB. At the same time PARPi prevent single-strand break repair 
which is also followed by DSB [2]. 
The Role of Platinum-Based Chemotherapy in  
Patients with BRCA-Associated Breast Cancer
Carboplatin acts on the Achilles heel of BRCA-deficient tumors; 
they are no longer capable of homologous repair which is the most 
reliable DNA repair mechanism in the presence of DBS caused by 
platinum adducts [3–5]. Whereas healthy body cells are heterozy-
gous for the BRCA germline mutation, in tumor cells due to a sec-
ond hit the intact allele is lost and tumor cells are predominantly 
prone to apoptosis after treatment with carboplatin. Although 
there is not yet enough data from randomized controlled clinical 
trials to support platinum as standard treatment in BRCA-associ-
ated breast cancer, in vitro and in vivo data indicate a particular 
sensitivity to platinum-based therapy. In BRCA1 carriers with 
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Summary
The introduction of an increasing number of individual-
ized molecular targeted therapies into clinical routine 
mirrors their importance in modern cancer prevention 
and treatment. Well-known examples for targeted agents 
are the monoclonal antibody trastuzumab and the selec-
tive estrogen receptor modulator tamoxifen. The identifi-
cation of an unaltered gene in tumor tissue in colon can-
cer (KRAS) is a predictor for the patient’s response to 
targeted therapy with a monoclonal antibody (cetuxi-
mab). Targeted therapy for hereditary breast and ovarian 
cancer has become a reality with the approval of olapa-
rib for platin-sensitive late relapsed BRCA-associated 
ovarian cancer in December 2014. This manuscript re-
views the status quo of poly-ADP-ribose polymerase in-
hibitors (PARPi) in the therapy of breast and ovarian can-
cer as well as the struggle for carboplatin as a potential 
standard of care for triple-negative and, in particular, 
BRCA-associated breast cancer. Details of the mecha-
nism of action with information on tumor development 
are provided, and an outlook for further relevant re-
search is given. The efficacy of agents against molecular 
targets together with the identification of an increasing 
number of cancer-associated genes will open the flood-
gates to a new era of treatment decision-making based 
on molecular tumor profiles. Current clinical trials in-
volving patients with BRCA-associated cancer explore 
the efficacy of the molecular targeted therapeutics plati-
num and PARPi.
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breast cancer an amazing tumor response rate after neoadjuvant 
chemotherapy with cisplatin was reported [6–8]. 
Additionally a higher response to neoadjuvant chemotherapy 
with cisplatin was described in triple-negative breast cancers 
(TNBC) with germline or somatic BRCA1/2 mutations compared 
to non-cisplatin chemotherapy [9]. The reason for the increased 
sensitivity of TNBC to platinum might be that about 15% of these 
heterogenous tumors are BRCA-associated with mostly BRCA1 
and rarely BRCA2 harboring the underlying mutation [10, 11]. The 
histopathologic features of TNBC serve as surrogate marker for 
high genomic instability and response to DNA-damaging agents 
such as the DNA crosslinkers carboplatin and cisplatin [12]. 
Most recently GeparSixto, a prospective randomized controlled 
phase II clinical trial, reported that the addition of carboplatin 
(weekly carboplatin, area under the curve 2) to neoadjuvant chem-
otherapy significantly improved the pathologic complete response 
(pCR) rate in patients with TNBC (n = 315) from 44 to 64% irre-
spective of BRCA status and family history [15]. 
Furthermore the addition of carboplatin to standard neoadju-
vant chemotherapy increased pCR rates in patients with TNBC in 
the CALGB 40603 study [13]. In this phase II trial patients with 
TNBC (n = 433) received paclitaxel with or without bevacizumab 
and/or carboplatin. The 4 treatment arms were followed by dose-
dense chemotherapy with doxorubicin and cyclophosphamide. A 
pCR rate of 54% was reported in patients receiving carboplatin and 
41% in patients treated without carboplatin. 
In addition Tutt et al. [14] at the San Antonio Breast Cancer 
Symposium 2014 presented the TNT trial, a phase III study in first-
line treatment of patients with TNBC containing a subgroup of 43 
BRCA1 of BRCA2 mutation carriers. After 6 cycles of carboplatin 
or docetaxel a longer progression-free survival (PFS) in carriers 
(6.8 months) compared to non-carriers (3.1 months) was demon-
strated. In contrast to the data of von Minckwitz et al. [15] the 
TNT trial did not find a superior response with carboplatin com-
pared to standard therapy in the whole group of TNBC patients. 
The reason might have been the different treatment settings com-
paring palliative to adjuvant therapy. Due to the intratumoral het-
erogeneity that derives from genomic instability and selection 
pressure under chemotherapy, the tumor might change its main 
features [11]. Even reconstitution of homologous repair in plati-
num-resistant ovarian cancer cells was described [16]. Advanced 
BRCA-associated breast cancer might therefore behave differently 
to primary early breast cancer. 
Platinum-Based Chemotherapy in Patients with 
BRCA-Associated Ovarian Cancer
Moreover there is clinical evidence for the efficacy of platinum 
in patients with BRCA mutations derived from ovarian cancer tri-
als. A pooled analysis of 26 observational studies on the survival of 
women with epithelial ovarian cancer (EOC) included data from 
1,213 EOC cases with pathogenic germline mutations in BRCA1 (n 
= 909) or BRCA2 (n = 304) and from 2,666 non-carriers recruited 
and followed up at variable times between 1987 and 2010 [17]. 
Among patients with invasive EOC having a germline mutation in 
BRCA1 or BRCA2 was associated with improved 5-year overall sur-
vival (OS). BRCA2 carriers had the best prognosis. Irrespective of 
family history around 15% of non-mucinous ovarian carcinomas 
and 11–22% of high-grade serous ovarian cancers are BRCA1/2-as-
sociated [18, 19]. In the presence of a family history of breast or 
ovarian cancer mutation frequency rises to 40% and higher depend-
ent on age of onset and number of affected relatives [20]. 
Platinum-Based Chemotherapy So Far No Standard 
in BRCA-Associated Breast Cancer
The above data lead to the presently observable tendency of on-
cologists to add platinum to chemotherapy regimens for BRCA 
mutation carriers with breast cancer outside of trial concepts, and 
this tendency will also increase for women with TNBC; therefore a 
prospectively planned randomized controlled trial is highly neces-
sary. By means of a translational research program this trial will 
provide the rationale for further studies in sporadic breast cancers 
with a BRCAness phenotype that may account for up to 20% of all 
breast cancers [21]. These women may also benefit from the addi-
tion of platinum compounds and other agents targeting the BRCA 
signaling pathway (e.g. PARPi). Therefore the German Consor-
tium of Hereditary Breast and Ovarian Cancer (GC-HBOC) estab-
lished the NeoFam trial (supported by the Deutsche Forschungsge-
meinschaft) for comparison of weekly carboplatin with paclitaxel 
after standard anthracyline-containing neoadjuvant therapy of pa-
tients with BRCA1/2-positive early breast cancer (EudraCT num-
ber: 2014–004737–51).
The Role of PARP Inhibitors in Patients with BRCA-
Associated Breast and Ovarian Cancer
PARPi selectively produce cell death in BRCA-deficient tumor 
cells via ‘synthetic lethality’. This term describes the inactivation of 
1 of the 2 most important alternative cell mechanisms in a cancer 
cell which prevent fatal cell damage in the first place. The addi-
tional inactivation of the residual ‘rescuing’ mechanism by a tar-
geted drug finally induces tumor cell death. However further mod-
els try to explain the function of PARPi including not only the in-
volvement in single-strand break repair but also the activation of 
another alternative DNA repair process, non-homologous end 
joining. Therefore PARPi are very promising drugs within treat-
ment concepts against BRCA-associated cancers and may also be 
efficient in cancers associated with other mutated homologous re-
combination genes. 3  members of the 18-member PARP family 
(PARP1, 2, and 3) that have been identified in mammalian cells are 
linked to DNA repair [22]. Most preclinical and clinical data fo-
cusses on the role of PARP1 in DNA repair, regulation of genomic 
stability in the cell, or involvement in cellular energy mechanisms 
as a target of PARPi [23]. The different models describing the cel-
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lular functions of PARP and the mechanisms of PARPi to selec-
tively kill homologous recombination-deficient tumor cells might 
explain why some cancers respond to PARPi and others do not. 
Therefore further preclinical investigations and clinical trials are 
needed to analyze the different antitumoral effects of PARPi.
Approval of PARPi Olaparib for BRCA-Associated 
Ovarian Cancer
The PARPi which is currently developed furthest for clinical use 
is olaparib (LynparzaTM, AstraZeneca, Wilmington, DE, USA). It is 
directed against PARP1, PARP2, and PARP3. In December 2014 
the FDA and EMA granted accelerated approval for maintenance 
therapy after platinum chemotherapy for relapsed high-grade se-
rous ovarian/fallopian/peritoneal cancer (HGSOC) in patients with 
a germline (FDA, EMA) or somatic (EMA) mutation in the breast 
cancer genes BRCA1 or BRCA2. Proof-of-concept phase I/II trials 
in BRCA1/2 mutation carriers with advanced breast and ovarian 
cancer extended first findings about the clinical effect of single 
agent activity of olaparib from phase I dose escalation trials [24, 
25]. Recent data from a randomized, placebo-controlled, phase II 
trial in a maintenance setting with patients who are most likely to 
benefit from PARPi due to a BRCA mutation and platinum-re-
sponsive relapsed ovarian cancer lead to the approval in the US 
and the EU. The authors observed an increased median PFS of 8.4 
versus 4.8 months after 2 or more lines of platinum-based therapy. 
This is the first new agent that brought such an improvement in 
ovarian cancer since bevacizumab in 2011 [26–28]. An interim 
analysis with 58% maturity showed differences between olaparib 
and placebo, in the BRCA1/2 mutation carriers with a hazard ratio 
(HR) of 0.18 (95% confidence interval 0.11–0.31) and a median 
PFS of 11.2 vs. 4.3 months, respectively. OS did not show a differ-
ence in this group, (HR = 0.74; median OS 34.9 vs. 31.9 months) 
probably due to the 22.6% of patients on placebo who switched to 
olaparib. Olaparib is an oral PARPi that is currently under further 
investigation e.g. within the SOLO1 and SOLO2 phase III trials. It 
is given after a platinum-containing chemotherapy. To be eligible 
SOLO1 patients have to display a good response to the first plati-
num-based chemotherapy for advanced (FIGO stage III–IV) pri-
mary ovarian, fallopian, or peritoneal cancer. The SOLO2 trial fo-
cuses on patients with platinum-sensitive relapse. At the same time 
accumulating data exists for prolongation of disease-free survival 
in HGSOC with and without mutations in BRCA1 or BRCA2 [29].
Two proof-of-principle trials with BRCA germline mutation car-
riers demonstrated similar response rates with olaparib in breast 
and ovarian cancer [24, 25]. In breast cancer current trials concen-
trate on palliative therapy of metastasized germline BRCA1/2-mu-
tated breast cancer after several lines of chemotherapy. (Neo-)adju-
vant trial concepts focus on maintenance therapy post chemother-
apy and surgery (OlympiA trial and Brightness by German Breast 
Group). In the OlympiA trial patients with TNBC and elevated risk 
for recurrence receive treatment with olaparib versus placebo for 12 
months after neoadjuvant chemotherapy and surgery or following 
adjuvant chemotherapy. Several other trials for patients with breast 
cancer in different therapy indications and with a variety of PARPi, 
e.g. veliparib, rucaparib, niraparib, are under way. Iniparib, origi-
nally assumed to be an active PARPi, in a phase III trial in combina-
tion with carboplatin/gemcitabine in patients with metastasized 
breast cancer failed and is no longer considered a PARPi [30–32]. 
Side effects of the different effective oral PARPi are consistent 
with mostly grade 2 toxicity for e.g. nausea, fatigue, anemia, diar-
rhea, dysgeusia, and thrombocytopenia. Rare side effects include 
myelodysplastic syndrome, acute myeloid leukemia (AML), and 
pneumonitis. Because of their seriousness these side effects could 
impede the development of PARPi in primary prevention [33]. Fu-
ture development now aims to increase bioavailability for less tab-
let intake per day, which ranges at present between 2 × 8 and 1 × 1 
tablets.
Combined Therapy with PARPi and Carboplatin
Current therapeutic concepts of multiple PARPi focus not only 
on PARPi as single agents but also in combination with various 
DNA-damaging agents. Optimal timing of therapy and selection of 
patients with highest benefit beyond BRCA mutation carriers is 
still the subject of research. Studies have shown clinical benefit and 
interactive adverse events, including bone marrow toxicity and fa-
tigue [29, 34, 35]. Moreover PARPi might function as a sensitizer 
to platinum-based chemotherapy or radiation [36]. Therefore in-
termittent intake of oral PARPi starting a few days before plati-
num-containing chemotherapy is a very interesting approach. As a 
next step another phase III trial, PAOLA1, is investigating the con-
current use of olaparib versus placebo with first-line platinum-con-
taining chemotherapy plus bevacizumab in advanced high-grade 
ovarian/fallopian/peritoneal cancer independent of a germline mu-
tation. In breast cancer BROCADE3 offers treatment with carbopl-
atin and paclitaxel in combination with intermittent application of 
veliparib versus placebo to BRCA1/2-associated advanced or me-
tastasized disease. 
BRCAness: Treatment Options Beyond the Germline 
Mutation Status
As mentioned before PARPi might be efficient in carcinomas 
with impaired repair mechanism of homologous recombination. 
Recent data indicate that up to 50% of HGSOC might be caused by 
homologous repair deficiency (HRD) [37]. HRD might be the re-
sult of germline BRCA1/2 mutations which are found in approxi-
mately 15% of EOC, somatic BRCA1/2 mutations (approximately 
7% of HGSOC), mutations in other genes affecting proteins in-
volved in homologous recombination (e.g. RAD51C, RAD51D, 
ATM, CHEK2), and functional silencing of genes concerning the 
homologous recombination mechanism (10% of HGSOC) [11, 
19–23]. This phenomenon is referred to as ‘BRCAness’, and differ-
ent strategies are being followed to establish a routine test for its 
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detection in tumor tissue in paraffin material. So far preparation of 
tumor DNA and sequencing of BRCA1/2 and other genes involved 
in homologous recombination is the most reliable but also the 
most costly strategy. Moreover mutations of unknown significance 
cause difficulties in the interpretation of the analysis. Great efforts 
are currently being made to establish a functional test for HRD. All 
current trials are accompanied by large biomarker projects that re-
quire collection of blood and tumor material.
Similar to HER2-directed therapies indication for treatment 
with PARPi might be dependent on a test which is performed on 
tumor tissue in paraffin. If testing of tumor material is performed 
first, genetic counselling is recommended for patients with somatic 
BRCA1/2 mutations because a germline mutation will be found in 
more than half of them. A germline mutation in BRCA1 or BRCA2 
implies the known risk for secondary cancer and cancer risk for 
consanguineous relatives [16].
Outlook
The inclusion of targeted agents such as platinum and PARPi in 
anticancer therapy of BRCA1/2 mutation carriers and BRCAness 
cancers has unleashed future challenges. There are a lot of unre-
solved questions: How can we select the patients who are most 
likely to benefit? A deleterious germline mutation in the BRCA 
genes is a predictive marker for the use of PARPi. Analysis cur-
rently involves various sequencing methods and screening for large 
deletions or insertions by multiplex ligand probe analysis; however 
are there other tools with which to identify susceptible patients 
with methylation of BRCA genes or somatic mutations? Moreover 
BRCA-like gene expression profiles in BRCA1/2-negative familial 
and sporadic carcinomas (e.g. TNBC) may show the same response 
rates to platinum or PARPi as carcinomas of BRCA mutation carri-
ers. Does the impairment of other homologous recombination 
genes indicate potential drug response? What is the optimal tim-
ing, dosage, scheduling, and sequencing of PARPi? Could severe 
adverse events like AML preclude the use of PARPi in primary pre-
vention? What are the mechanisms of resistance to PARPi, and 
how can they be overcome? 
Conclusion
Approval of PARPi in BRCA1/2-assoiated ovarian cancer gives 
way to a new kind of medication that targets not only the germline 
mutation but also the resulting deficiency, HRD, which is often 
found in HGSOC and TNBC. Highly interesting trials with differ-
ent oral PARPi are ongoing for both tumor entities in various ther-
apy settings. Current trials with targeted agents are supported by 
concepts of identifying and validating predictive biomarkers for 
the stratification of patients. These data will further advance the 
field of targeted therapy. Besides, chemotherapy with carboplatin is 
becoming more and more important for the treatment of TNBC 
with or without BRCA1 and BRCA2 mutations; however further 
studies are needed. 
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